Clover Health Investments ( NASDAQ:CLOV – Get Rating ) had its price objective decreased by Canaccord Genuity Group from $4.00 to $3.00 in a research note released on Monday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock. Several other equities analysts have also weighed in on the stock. Canaccord Genuity Group cut their price objective on shares of Clover Health Investments from $7.00 to $4.00 in a report on Tuesday, November 8th. Credit Suisse Group reduced their price target on Clover Health Investments from $2.

https://www.dailypolitical.com/2023/03/10/canaccord-genuity-group-trims-clover-health-investments-nasdaqclov-target-price-to-3-00.html

#dailypolitical